Skip to main content

Table 1 Baseline characteristics of the study patients

From: Prognosis of hemodialysis patients with progressive aortic stenosis: a prospective cohort study

Parameter

Patients with progressive AS

Patients without AS

P

Number of patients

35

248

 

Age (year)

74 ± 11

67 ± 12

< 0.001

Male gender, n (%)

20 (57)

144 (58)

1.00

Body mass index (kg/m2)

21.0 ± 4.0

21.9 ± 4.6

0.27

Length of time on dialysis (year)

12 ± 9

9 ± 9

0.08

Specific Activity Scale (METs)

3.5 ± 2.0

4.3 ± 2.1

0.03

Exercise-related symptoms, n (%)

 Syncope

5 (14)

16 (7)

0.16

 Chest pain

7 (20)

54 (22)

1.00

 Shortness of breath

12 (34)

65 (26)

0.32

 Symptom, any of the above

12 (34)

98 (40)

0.59

Coexisting conditions, n (%)

 Diabetes

13 (37)

107 (43)

0.59

 Hypertension

30 (86)

192 (77)

0.38

 Dyslipidemia

14 (40)

101 (41)

1.00

 Ischemic heart disease

9 (26)

60 (24)

0.84

 Heart failure

11 (31)

45 (18)

0.07

 Atrial fibrillation

3 (8)

26 (11)

1.00

 Peripheral artery disease

20 (57)

75 (30)

0.004

  History of PTA or limb amputation

8 (23)

34 (14)

0.20

 Cerebrovascular disease

9 (26)

51 (21)

0.51

 Past or present tobacco use

15 (43)

102 (41)

0.86

Medications, n (%)

 ACE inhibitor

1 (3)

9(4)

1.00

 ARB

14 (40)

93 (38)

0.85

 Calcium channel blocker

22 (63)

132 (53)

0.37

 Beta blocker

10 (29)

91 (37)

0.45

 Statin

14 (40)

101 (41)

1.00

 Vitamin D3

14 (40)

127 (51)

0.28

 Phosphate binder

13 (37)

88 (35)

0.85

 Calcimimetics

5 (14)

29 (12)

0.59

 Calcium carbonate

26 (74)

160 (65)

0.34

Blood test results

 Hemoglobin (g/dL)

10.7 ± 1.3

10.8 ± 1.1

0.72

 Albumin (g/dL)

3.5 ± 0.4

3.6 ± 0.4

0.08

 Adjusted calcium (mg/dL)

9.2 ± 0.6

9.0 ± 0.8

0.12

 Phosphorus (mg/dL)

5.1 ± 1.4

5.4 ± 1.3

0.27

 Calcium–phosphorus product (mg2/dL2)

47.9 ± 12.7

47.2 ± 13.2

0.78

 C-reactive protein (mg/dL)

2.1 ± 5.4

0.6 ± 1.9

0.18

 LDL cholesterol (mg/dL)

81 ± 24

81 ± 22

0.68

  1. ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, AS aortic stenosis, LDL low-density lipoprotein, METs metabolic equivalents, PTA percutaneous transluminal angioplasty